An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study-Reference-Cited by-同舟云学术

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

Published:2023-01 Issue:10372 Volume:401 Page:204-214
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Guttman-Yassky Emma,Simpson Eric L,Reich Kristian,Kabashima Kenji,Igawa Ken,Suzuki Tetsuya,Mano Hirotaka,Matsui Takeshi,Esfandiari Ehsanollah,Furue Masutaka

Funder

Kyowa Kirin Co Ltd

Kyowa Kirin Pharmaceutical Development

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016

2. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis;Achten;J Allergy Clin Immunol Pract,2021

3. Neuroimmune interactions in chronic itch of atopic dermatitis;Yosipovitch;J Eur Acad Dermatol Venereol,2020

4. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies;Brunner;J Allergy Clin Immunol,2017

5. Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council;Renert-Yuval;J Allergy Clin Immunol,2021

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atopic dermatitis and IgE-mediated food allergy;Annals of Allergy, Asthma & Immunology;2024-09

2. Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments;International Immunopharmacology;2024-09

3. Current and Emerging Biologics for Atopic Dermatitis;Immunology and Allergy Clinics of North America;2024-09

4. Biologic and Small Molecule Therapy in Atopic Dermatitis;Biomedicines;2024-08-13

5. Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds;Allergy;2024-08-08